Skip to main content

Table 4 Total QALYs, total costs, and incremental cost-effectiveness ratios for scenarios 2, 4, 6 and 8a

From: Health economic evaluation of Human Papillomavirus vaccines in women from Venezuela by a lifetime Markov cohort model

Scenario

Quadrivalent vs No vaccination

Bivalent vs No vaccination

Bivalent vs Quadrivalent

∆QALYs

∆COSTS

ICER

∆QALYs

∆COSTS

ICER

∆QALYs

∆COSTS

ICER

Scenario

 2: Both vaccines = 8.5 US$;

 2-dose scheme - FX 6.3

4,395

−805.7 US$

cost-saving

4,486

−735.9 VEF

cost- saving

91

69.8 VEF

0.77

 4: Both vaccines = 8.5 US$;

 2-dose scheme - FX: 170

−106.4 US$

cost- saving

−36.6 VEF

cost- saving

69.8 VEF

0.77

 6: BV: 8.5 US$ QV: 13.79 US$;

 2-dose scheme - FX 6.3

−788.9 US$

cost- saving

−735.9 VEF

cost- saving

53.0 VEF

0.58

 8: BV: 8.5 US$ QV: 13.79 US$;

 2-dose scheme - FX: 170

345.5 US$

0.08

−36.6 VEF

cost-saving

−382.1 VEF

cost-saving

  1. Notes: Results for a cohort of 264,489 women (discount = 5%)
  2. Abbreviations: FX exchange rate (VEF per US$), QV quadrivalent, BV bivalent. GDP per capita: 104,404 VEF. [68] (See scenarios 1, 3, 5, 7 in Additional file 1: Table S2), QALYs quality-adjusted life years, ICER incremental cost-effectiveness ratio, VEF Venezuelan bolívar fuerte, US$ United States dollar
  3. aCosts and ICERs are expressed in millions of VEF, 2015